Replies to post #140668 on Biotech Values

[rkrw]

So in other words, the Baxter deal was 30% better than they had expected? :)

[rwwine]

Advancement of Copaxone—regulatory. . . 10% 70% 7.0%

Advancement of Copaxone—development . . 10% 70% 7.0%

I find this "assessment" somewhat bothering in that they are not all that bullish on their own efforts on m-Copaxone and where things stand today. Anyone else draw the same inference?